Steve A. Shallcross, CEO, and Manel Cascallo, General Director, EU Subsidiary of Theriva Biologics, Inc TOVX, recently presented at Benzinga's Virtual HealthCare Summit 2024.
Theriva is a clinical-stage biotech developing therapies designed to treat cancer and related diseases in areas of high unmet need. The company is developing a platform that is based on an adenovirus and is administered through IV.
The company's lead candidate, VCN-01, is currently undergoing a phase 2 trial, the VIRAGE study, initiated in Q4 of 2022.
Learn more here:
Featured photo by Fusion Medical Animation on Unsplash.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
